Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MRNA |
---|---|---|
09:32 ET | 78123 | 118.2999 |
09:34 ET | 40978 | 118.115 |
09:36 ET | 41956 | 118.88 |
09:38 ET | 51768 | 118.25 |
09:39 ET | 44026 | 118.87 |
09:41 ET | 22995 | 118.315 |
09:43 ET | 54832 | 117.965 |
09:45 ET | 18080 | 117.2086 |
09:48 ET | 15557 | 116.985 |
09:50 ET | 6904 | 117.035 |
09:52 ET | 8901 | 116.865 |
09:54 ET | 11672 | 117.4 |
09:56 ET | 6396 | 116.85 |
09:57 ET | 12089 | 116.605 |
09:59 ET | 1657 | 116.46 |
10:01 ET | 3791 | 116.24 |
10:03 ET | 54802 | 115.3 |
10:06 ET | 35771 | 114.4998 |
10:08 ET | 23709 | 115.32 |
10:10 ET | 15873 | 115.3 |
10:12 ET | 26097 | 114.7762 |
10:14 ET | 20162 | 114.645 |
10:15 ET | 6558 | 114.7 |
10:17 ET | 13257 | 114.465 |
10:19 ET | 6463 | 114.655 |
10:21 ET | 24922 | 114.6764 |
10:24 ET | 7016 | 114.65 |
10:26 ET | 7417 | 114.71 |
10:28 ET | 35092 | 114.11 |
10:30 ET | 9219 | 114.3002 |
10:32 ET | 13221 | 114.9 |
10:33 ET | 13760 | 114.95 |
10:35 ET | 7752 | 114.655 |
10:37 ET | 15388 | 114.58 |
10:39 ET | 5921 | 114.58 |
10:42 ET | 11004 | 114.99 |
10:44 ET | 8614 | 114.98 |
10:46 ET | 7563 | 114.66 |
10:48 ET | 4743 | 114.765 |
10:50 ET | 6040 | 114.9426 |
10:51 ET | 11247 | 115.2399 |
10:53 ET | 9842 | 115 |
10:55 ET | 3459 | 115.42 |
10:57 ET | 9629 | 115.7 |
11:00 ET | 7518 | 115.59 |
11:02 ET | 2925 | 115.45 |
11:04 ET | 8517 | 115.38 |
11:06 ET | 11382 | 115.475 |
11:08 ET | 19601 | 115.565 |
11:09 ET | 7869 | 115.4 |
11:11 ET | 3075 | 115.43 |
11:13 ET | 7394 | 115.23 |
11:15 ET | 8612 | 115.38 |
11:18 ET | 7837 | 115.8053 |
11:20 ET | 30611 | 116.605 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Moderna Inc | 44.4B | -7.4x | --- |
ICON PLC | 26.2B | 38.6x | +4.68% |
Biogen Inc | 33.7B | 28.7x | -18.14% |
Biontech SE | 18.7B | 154.3x | --- |
Grifols SA | 5.3B | 20.7x | --- |
Alnylam Pharmaceuticals Inc | 30.8B | -91.4x | --- |
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $44.4B |
---|---|
Revenue (TTM) | $5.2B |
Shares Outstanding | 383.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.67 |
EPS | $-15.66 |
Book Value | $36.27 |
P/E Ratio | -7.4x |
Price/Sales (TTM) | 8.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -99.73% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.